We are live on ! Find out more
OVID icon

Ovid Therapeutics
OVID

81 hedge funds and large institutions have $47.1M invested in Ovid Therapeutics in 2025 Q3 according to their latest regulatory filings, with 25 funds opening new positions, 17 increasing their positions, 24 reducing their positions, and 14 closing their positions.

New
Increased
Maintained
Reduced
Closed

297% more capital invested

Capital invested by funds: $11.9M → $47.1M (+$35.2M)

79% more first-time investments, than exits

New positions opened: 25 | Existing positions closed: 14

14% more funds holding

Funds holding: 71 → 81 (+10)

0.35% more ownership

Funds ownership: 50.58% → 50.92% (+0.35%)

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

29% less repeat investments, than reductions

Existing positions increased: 17 | Existing positions reduced: 24

34% less call options, than puts

Call options by funds: $299K | Put options by funds: $456K

Holders
81
Holders Change
+10
Holders Change %
+14.08%
% of All Funds
1.06%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.01%
New
25
Increased
17
Reduced
24
Closed
14
Calls
$299K
Puts
$456K
Net Calls
-$157K
Net Calls Change
-$162K

Top Buyers

1
AAA
Affinity Asset Advisors
New York
+$1.72M
2
IC
Ikarian Capital
Texas
+$950K
3
SSA
Schonfeld Strategic Advisors
New York
+$765K
4
Balyasny Asset Management
Balyasny Asset Management
Illinois
+$542K
5
Marshall Wace
Marshall Wace
United Kingdom
+$536K

Top Sellers

1
BI
BVF Inc
California
-$1.27M
2
SCM
Sio Capital Management
New York
-$697K
3
BlackRock
BlackRock
New York
-$657K
4
TA
TLS Advisors
Florida
-$574K
5
MAP
Madison Avenue Partners
New York
-$433K
Name Holding Trade Value Shares
Change 		Change in
Stake
TPC
1
Takeda Pharmaceutical Company
Japan
$9.79M – – –
Vanguard Group
2
Vanguard Group
Pennsylvania
$3.67M +$160K +184,698 +7%
AAA
3
Affinity Asset Advisors
New York
$3.44M +$1.72M +1,982,484 +297%
Acadian Asset Management
4
Acadian Asset Management
Massachusetts
$2.97M +$154K +178,169 +8%
Renaissance Technologies
5
Renaissance Technologies
New York
$2.62M -$67K -77,285 -4%
SCM
6
Sio Capital Management
New York
$1.86M -$697K -804,505 -36%
DCM
7
Driehaus Capital Management
Illinois
$1.82M – – –
Adage Capital Partners
8
Adage Capital Partners
Massachusetts
$1.75M +$173K +200,000 +17%
KCM
9
Kennedy Capital Management
Missouri
$1.44M -$343K -395,691 -26%
IC
10
Ikarian Capital
Texas
$1.42M +$950K +1,095,574 New
Millennium Management
11
Millennium Management
New York
$1.28M -$57.2K -66,041 -6%
Assenagon Asset Management
12
Assenagon Asset Management
Luxembourg
$1.2M +$424K +488,956 +112%
SSA
13
Schonfeld Strategic Advisors
New York
$1.15M +$765K +883,154 New
Marshall Wace
14
Marshall Wace
United Kingdom
$1.02M +$536K +618,932 +376%
Wells Fargo
15
Wells Fargo
California
$950K -$28.1K -32,398 -4%
Geode Capital Management
16
Geode Capital Management
Massachusetts
$843K +$4.06K +4,685 +0.7%
Balyasny Asset Management
17
Balyasny Asset Management
Illinois
$813K +$542K +625,000 New
BlackRock
18
BlackRock
New York
$795K -$657K -757,695 -55%
Walleye Capital
19
Walleye Capital
New York
$776K +$517K +596,717 New
Susquehanna International Group
20
Susquehanna International Group
Pennsylvania
$766K +$311K +358,849 +156%
BFM
21
Boothbay Fund Management
New York
$633K +$422K +486,877 New
Citadel Advisors
22
Citadel Advisors
Florida
$527K +$351K +405,382 New
Simplex Trading
23
Simplex Trading
Illinois
$503K +$336K +387,512 New
Bank of America
24
Bank of America
North Carolina
$472K +$301K +347,799 +2,333%
Two Sigma Investments
25
Two Sigma Investments
New York
$443K +$296K +341,134 New
1
2 3 4

OVID Hedge Fund Activity: Q3 2025 in Review

81 of the 7,619 institutional investors tracked by Wall St. Rank reported a position in Ovid Therapeutics (OVID) for Q3 2025, worth a combined $47.1M — up 297% from $11.9M a quarter earlier.

Buyers outnumbered sellers: 25 funds opened new OVID positions and 14 closed out — a net gain of 11 holders — while 17 added to existing stakes and 24 trimmed.

The largest buyer was Affinity Asset Advisors, adding an estimated $1.72M. The largest seller was BVF Inc, exiting entirely with an estimated $1.27M sold.

  • 81 institutional investors held Ovid Therapeutics (OVID) as of Q3 2025, up from 71 in Q2 2025.
  • Funds reported $47.1M of Ovid Therapeutics stock for Q3 2025, up 297% quarter-over-quarter.
  • 25 funds opened new Ovid Therapeutics positions in Q3 2025 and 14 closed out, a net change of +11 holders.
  • The largest Ovid Therapeutics buyer in Q3 2025 was Affinity Asset Advisors, an estimated $1.72M added.
  • The largest Ovid Therapeutics seller in Q3 2025 was BVF Inc, an estimated $1.27M sold.

Based on aggregated 13F filings for Q3 2025.